Skip to main content
SpringerLink
Log in

Specific issues

  • Chapter
  • First Online:
Book cover Advanced Handbook of Systemic Lupus Erythematosus

  • 1586 Accesses

Abstract

Maximum age limits ranging from 14 to 20 years of age have been inconsistently used to define childhood-onset systemic lupus erythematosus (SLE) [1], and this variation has strongly impaired the comparability of previous pediatric SLE studies. Therefore, and despite many recent advances, including the recognition of greater role of genetic background [2], the epidemiology, optimal management and long term outcomes of pediatric lupus remain poorly known.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • 1 Silva CA, Avcin T, Brunner HI. Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res (Hoboken). 2012;64:1787–1793.

    Google Scholar 

  • 2 Webb R, Kelly JA, Somers EC, et al. Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. Ann Rheum Dis. 2011;70:151–6.

    Google Scholar 

  • 3 Arnaud L, Fagot JP, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev. 2014;13:1082–1089.

    Google Scholar 

  • 4 Hiraki LT, Feldman CH, Liu J, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2012;64:2669–2676.

    Google Scholar 

  • 5 Son MB, Johnson VM, Hersh AO, Lo MS, Costenbader KH. Outcomes in hospitalized pediatric patients with systemic lupus erythematosus. Pediatrics. 2014;133:e106–113.

    Google Scholar 

  • 6 Watson L, Leone V, Pilkington C, et al. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum. 2012;64:2356–2365.

    Google Scholar 

  • 7 Sato JO, Corrente JE, Saad-Magalhaes C. Chronic active disease pattern predicts early damage in juvenile systemic lupus erythematosus. Lupus. 2015;24:1421–1428.

    Google Scholar 

  • 8 Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus. 2011;20:1345–1355.

    Google Scholar 

  • 9 Gormezano NW, Silva CA, Aikawa NE, Barros DL, da Silva MA, Otsuzi CI, et al. Chronic arthritis in systemic lupus erythematosus: distinct features in 336 paediatric and 1830 adult patients. Clin Rheumatol. 2016;35:227–231.

    Google Scholar 

  • 10 Marques VL, Gormezano NW, Bonfa E, et al. Pancreatitis subtypes survey in 852 childhood-onset systemic lupus erythematosus patients. J Pediatr Gastroenterol Nutr. 2016;62:328–334.

    Google Scholar 

  • 11 Janssens P, Arnaud L, Galicier L, Mathian A, Hie M, Sene D, et al. Lupus enteritis: from clinical findings to therapeutic management. Orphanet J Rare Dis. 2013;8:67.

    Google Scholar 

  • 12 Bader-Meunier B, Armengaud JB, Haddad E, et al. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr. 2005;146:648–653.

    Google Scholar 

  • 13 Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152:550–556.

    Google Scholar 

  • 14 Levy DM, Peschken CA, Tucker LB, et al. Influence of ethnicity on childhood-onset systemic lupus erythematosus: results from a multiethnic multicenter Canadian cohort. Arthritis Care Res (Hoboken). 2013;65:152–160.

    Google Scholar 

  • 15 Sag E, Tartaglione A, Batu ED, et al. Performance of the new SLICC classification criteria in childhood systemic lupus erythematosus: a multicentre study. Clin Exp Rheumatol. 2014;32:440–444.

    Google Scholar 

  • 16 Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–2686.

    Google Scholar 

  • 17 Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–1782.

    Google Scholar 

  • 18 Mina R, von Scheven E, Ardoin SP, Eberhard BA, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64:375–383.

    Google Scholar 

  • 19 Aragon E, Resontoc LP, Chan YH, et al. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis. Lupus. 2016;25:399–406.

    Google Scholar 

  • 20 Kizawa T, Nozawa T, Kikuchi M, et al. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis. Mod Rheumatol. 2015;25(2):210–4.

    Google Scholar 

  • 21 Tambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. J Rheumatol. 2015;42:541–546.

    Google Scholar 

  • 22 Woillard JB, Bader-Meunier B, Salomon R, et al. Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. Br J Clin Pharmacol. 2014;78:867–876.

    Google Scholar 

  • 23 Brunner HI, Silva CA, Reiff A, et al. Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2015;67:1377–1385.

    Google Scholar 

  • 24 Ardoin SP, Schanberg LE, Sandborg CI, et al. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis. 2014;73:557–566.

    Google Scholar 

  • 25 Knight AM, Weiss PF, Morales KH, Keren R. National trends in pediatric systemic lupus erythematosus hospitalization in the United States: 2000–2009. J Rheumatol. 2014;41:539–546.

    Google Scholar 

  • 26 Amaral B, Murphy G, Ioannou Y, Isenberg DA. A comparison of the outcome of adolescent and adult-onset systemic lupus erythematosus. Rheumatology (Oxford). 2014;53:1130–1135.

    Google Scholar 

  • 27 Bernatsky S, Clarke AE, Labrecque J, et al. Cancer risk in childhood-onset systemic lupus. Arthritis Res Ther. 2013;15:R198.

    Google Scholar 

  • 28 Costa-Reis P, Nativ S, Isgro J, et al. Major infections in a cohort of 120 patients with juvenile-onset systemic lupus erythematosus. Clin Immunol. 2013;149:442–449.

    Google Scholar 

  • 29 Arnaud L, Mathian A, Boddaert J, Amoura Z. Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment. Drugs Aging. 2012;29:181–189.

    Google Scholar 

  • 30 Boddaert J, Huong DL, Amoura Z, Wechsler B, Godeau P, Piette JC. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine. 2004;83:348–359.

    Google Scholar 

  • 31 Catoggio LJ, Soriano ER, Imamura PM, et al. Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup? Lupus. 2015;24:788–795.

    Google Scholar 

  • 32 Martinez-Barrio J, Ovalles-Bonilla JG, Lopez-Longo FJ, et al. Juvenile, adult and late-onset systemic lupus erythematosus: a long term follow-up study from a geographic and ethnically homogeneous population. Clin Exp Rheumatol. 2015;33:788–794.

    Google Scholar 

  • 33 Tomic-Lucic A, Petrovic R, Radak-Perovic M, et al. Late-onset systemic lupus erythematosus: clinical features, course, and prognosis. Clin Rheumatol. 2013;32:1053–1058.

    Google Scholar 

  • 34 Tan EM, Feltkamp TE, Smolen JS, Butcher B, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997;40:1601–1611.

    Google Scholar 

  • 35 Morel N, Bachelot A, Chakhtoura Z, et al. Study of anti-Mullerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013;98:3785–3792.

    Google Scholar 

  • 36 Vinet E, Labrecque J, Pineau CA, et al. A population-based assessment of live births in women with systemic lupus erythematosus. Ann Rheum Dis. 2012;71:557–559.

    Google Scholar 

  • 37 Borella E, Lojacono A, Gatto M, et al. Predictors of maternal and fetal complications in SLE patients: a prospective study. Immunol Res. 2014;60:170–176.

    Google Scholar 

  • 38 Buyon JP, Kim MY, Guerra MM, et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Annals of internal medicine. 2015;163(3):153–63.

    Google Scholar 

  • 39 Jakobsen IM, Helmig RB, Stengaard-Pedersen K. Maternal and foetal outcomes in pregnant systemic lupus erythematosus patients: an incident cohort from a stable referral population followed during 1990–2010. Scand J Rheumatol. 2015;44:377–384.

    Google Scholar 

  • 40 Koh JH, Ko HS, Lee J, et al. Pregnancy and patients with preexisting lupus nephritis: 15 years of experience at a single center in Korea. Lupus. 2015;24:764–772.

    Google Scholar 

  • 41 Saavedra MA, Cruz-Reyes C, Vera-Lastra O, et al. Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy. Clin Rheumatol. 2012;31:813–819.

    Google Scholar 

  • 42 Koh JH, Ko HS, Kwok SK, Ju JH, Park SH. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus. 2015;24:210–217.

    Google Scholar 

  • 43 Tedeschi SK, Massarotti E, Guan H, Fine A, Bermas BL, Costenbader KH. Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy. Lupus. 2015;24:1283–1292.

    Google Scholar 

  • 44 Clowse ME, Grotegut C. Racial and ethnic disparities in the pregnancies of women with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2016;68:1567–1572.

    Google Scholar 

  • 45 Chen TK, Gelber AC, Witter FR, Petri M, Fine DM. Renal biopsy in the management of lupus nephritis during pregnancy. Lupus. 2015;24:147–154.

    Google Scholar 

  • 46 Hoeltzenbein M, Elefant E, Vial T, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012;158A:588–596.

    Google Scholar 

  • 47 Wallenius M, Lie E, Daltveit AK, et al. No excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs. Arthritis Rheumatol. 2015;67:296–301.

    Google Scholar 

  • 48 Kaplan YC, Ozsarfati J, Nickel C, Koren G. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81:835–848.

    Google Scholar 

  • 49 Desai RJ, Huybrechts KF, Bateman BT, et al. Patterns and secular trends in use of immunomodulatory agents during pregnancy in women with rheumatologic conditions. Arthritis Rheumatol. 2016;68:1183–1189.

    Google Scholar 

  • 50 Saavedra MA, Sanchez A, Morales S, Angeles U, Jara LJ. Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome. Clin Rheumatol. 2015;34:1211–1216.

    Google Scholar 

  • 51 Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79:696–701.

    Google Scholar 

  • 52 Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499–1506.

    Google Scholar 

  • 53 Danve A, Perry L, Deodhar A. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report. Semin Arthritis Rheum. 2014;44:195–197.

    Google Scholar 

  • 54 Auyeung-Kim DJ, Devalaraja MN, Migone TS, Cai W, Chellman GJ. Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reprod Toxicol. 2009;28:443–455.

    Google Scholar 

  • 55 Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2004:CD004659.

    Google Scholar 

  • 56 Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S–736S.

    Google Scholar 

  • 57 Ost L, Wettrell G, Bjorkhem I, Rane A. Prednisolone excretion in human milk. J Pediatr. 1985;106:1008–1011.

    Google Scholar 

  • 58 Christensen LA, Dahlerup JF, Nielsen MJ, Fallingborg JF, Schmiegelow K. Azathioprine treatment during lactation. Aliment Pharmacol Ther. 2008;28:1209–1213.

    Google Scholar 

  • 59 Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. Am J Obstet Gynecol. 1972;112:978–980.

    Google Scholar 

  • 60 Moretti ME, Sgro M, Johnson DW, Sauve RS, Woolgar MJ, Taddio A, et al. Cyclosporine excretion into breast milk. Transplantation. 2003;75:2144–2146.

    Google Scholar 

  • 61 Izmirly PM, Llanos C, Lee LA, Askanase A, Kim MY, Buyon JP. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum. 2010;62:1153–1157.

    Google Scholar 

  • 62 Moretti D, Cimaz R, Vannucci G, Marino A, De Martino M, Greco A. Cutaneous neonatal lupus: a case report and review of the literature. Int J Dermatol. 2014;53:1508–1512.

    Google Scholar 

  • 63 Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum. 2004;50:3187–3194.

    Google Scholar 

  • 64 Eliasson H, Sonesson SE, Sharland G, et al. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation. 2011;124:1919–1926.

    Google Scholar 

  • 65 Izmirly PM, Saxena A, Kim MY, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation. 2011;124:1927–1935.

    Google Scholar 

  • 66 Chen CC, Lin KL, Chen CL, Wong AM, Huang JL. Central nervous system manifestations of neonatal lupus: a systematic review. Lupus. 2013;22:1484–1488.

    Google Scholar 

  • 67 Levesque K, Morel N, Maltret A, et al. Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. Autoimmun Rev. 2015;14:1154–1160.

    Google Scholar 

  • 68 Luo Y, Zhang L, Fei Y, et al. Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years–a retrospective cohort study. Clin Rheumatol. 2015;34:1721–1728.

    Google Scholar 

  • 69 Skog A, Lagnefeldt L, Conner P, Wahren-Herlenius M, Sonesson SE. Outcome in 212 anti-Ro/SSA-positive pregnancies and population-based incidence of congenital heart block. Acta Obstet Gynecol Scand. 2016;95:98–105.

    Google Scholar 

  • 70 Saxena A, McDonnell E, Ramos PS, et al. Preferential transmission of genetic risk variants of candidate loci at 6p21 from asymptomatic grandparents to mothers of children with neonatal lupus. Arthritis Rheum. 2012;64:931–939.

    Google Scholar 

  • 71 Neiman AR, Lee LA, Weston WL, Buyon JP. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr. 2000;137:674–680.

    Google Scholar 

  • 72 Salomonsson S, Sonesson SE, Ottosson L, Muhallab S, Olsson T, Sunnerhagen M, et al. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med. 2005;201:11–17.

    Google Scholar 

  • 73 Brucato A, Previtali E, Ramoni V, Ghidoni S. Arrhythmias presenting in neonatal lupus. Scand J Immunol. 2010;72:198–204.

    Google Scholar 

  • 74 Skog A, Eliasson H, Tingstrom J, et al. Long-term growth of children with autoantibody-mediated congenital heart block. Acta Paediatr. 2013;102:718–726.

    Google Scholar 

  • 75 Izmirly PM, Saxena A, Sahl SK, et al. Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. Ann Rheum Dis. 2016;75:1161–1165.

    Google Scholar 

  • 76 Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012;126:76–82.

    Google Scholar 

  • 77 Silverman E, Jaeggi E. Non-cardiac manifestations of neonatal lupus erythematosus. Scand J Immunol. 2010;72:223–225.

    Google Scholar 

  • 78 Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr. 2003;142:678–683.

    Google Scholar 

  • 79 Boros CA, Spence D, Blaser S, Silverman ED. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum. 2007;57:261–266.

    Google Scholar 

  • 80 Thomas G, Mancini J, Jourde-Chiche N, et al. Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis. Arthritis Rheumatol. 2014;66:2503–2511.

    Google Scholar 

  • 81 Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550–2557.

    Google Scholar 

  • 82 Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. New Engl J Med. 2003;349:2407–2415.

    Google Scholar 

  • 83 Manger K, Kusus M, Forster C, et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis. 2003;62:846–850.

    Google Scholar 

  • 84 Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New Engl J Med. 2003;349:2399–2406.

    Google Scholar 

  • 85 Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. New Engl J Med. 2003;349:2379–2380.

    Google Scholar 

  • 86 Urowitz MB, Ibanez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol. 2007;34:70–75.

    Google Scholar 

  • 87 Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford). 2004;43:924–929.

    Google Scholar 

  • 88 Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145:408–415.

    Google Scholar 

  • 89 Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 2012;176:708–719.

    Google Scholar 

  • 90 Kiani AN, Post WS, Magder LS, Petri M. Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology (Oxford). 2011;50:2071–2079.

    Google Scholar 

  • 91 Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003;62:1071–1077.

    Google Scholar 

  • 92 Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331–2337.

    Google Scholar 

  • 93 Urowitz M, Ibanez D, DD. G. Systemic Lupus International Collabo-rating Clinics (SLICC). Adjusted Framingham Risk Factor Scoring for systemiclupus erythematosus: results from an inception cohort followed for eight years. Arthritis Rheum. 2012;64:647.

    Google Scholar 

  • 94 Becker-Merok A, Nossent J. Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus. Lupus. 2009;18:508–515.

    Google Scholar 

  • 95 Mok CC, Wong CK, To CH, Lai JP, Lam CS. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2011;63:875–883.

    Google Scholar 

  • 96 Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis. 2011;70:760–765.

    Google Scholar 

  • 97 Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64:285–296.

    Google Scholar 

  • 98 Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20:206–218.

    Google Scholar 

  • 99 Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14:192–200.

    Google Scholar 

  • 100 Arnaud L, Mathian A, Ruffatti A, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2014;13:281–291.

    Google Scholar 

  • 101 Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010;62:863–868.

    Google Scholar 

  • 102 Rees F, Doherty M, Grainge M, Lanyon P, Davenport G, Zhang W. Burden of co-morbidity in systemic lupus erythematosus in the United Kingdom 1999–2012. Arthritis Care Res (Hoboken). 2016;68:819–827.

    Google Scholar 

  • 103 Yurkovich M, Vostretsova K, Chen W, Avina-Zubieta JA. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2014;66:608–616.

    Google Scholar 

  • 104 Yee CS, Su L, Toescu V, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology (Oxford). 2015;54:836–843.

    Google Scholar 

  • 105 Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine. 1999;78:167–175.

    Google Scholar 

  • 106 Feldman CH, Hiraki LT, Winkelmayer WC, et al. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol. 2015;67:1577–1585.

    Google Scholar 

  • 107 Luijten RK, Cuppen BV, Bijlsma JW, Derksen RH. Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections. Lupus. 2014;23:1512–1516.

    Google Scholar 

  • 108 Tektonidou MG, Wang Z, Dasgupta A, Ward MM. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996–2011. Arthritis Care Res (Hoboken). 2015;67:1078–1085.

    Google Scholar 

  • 109 Huang JL, Hung JJ, Wu KC, Lee WI, Chan CK, Ou LS. Septic arthritis in patients with systemic lupus erythematosus: salmonella and nonsalmonella infections compared. Semin Arthritis Rheum. 2006;36:61–67.

    Google Scholar 

  • 110 Chu AD, Polesky AH, Bhatia G, Bush TM. Active and latent tuberculosis in patients with systemic lupus erythematosus living in the United States. J Clin Rheumatol. 2009;15:226–229.

    Google Scholar 

  • 111 Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, Aguirre C. High risk of tuberculosis in systemic lupus erythematosus? Lupus. 2006;15:232–235.

    Google Scholar 

  • 112 Murray SG, Schmajuk G, Trupin L, et al. National lupus hospitalization trends reveal rising rates of herpes zoster and declines in pneumocystis pneumonia. PloS One. 2016;11:e0144918.

    Google Scholar 

  • 113 Ramos-Casals M, Cuadrado MJ, Alba P, et al. Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine. 2008;87:311–318.

    Google Scholar 

  • 114 Rasmussen NS, Draborg AH, Nielsen CT, Jacobsen S, Houen G. Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients. Scand J Rheumatol. 2015;44:143–149.

    Google Scholar 

  • 115 Chen J, Zhang H, Chen P, et al. Correlation between systemic lupus erythematosus and cytomegalovirus infection detected by different methods. Clin Rheumatol. 2015;34:691–698.

    Google Scholar 

  • 116 Subedi A, Magder LS, Petri M. Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus. Rheumatol Int. 2015;35:1687–1692.

    Google Scholar 

  • 117 Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11:R109.

    Google Scholar 

  • 118 Duffy KN, Duffy CM, Gladman DD. Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol. 1991;18:1180–1184.

    Google Scholar 

  • 119 Carli L, Tani C, Vagnani S, Signorini V, Mosca M. Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: prevalence and clinical impact--a systematic literature review. Semin Arthritis Rheum. 2015;45:190–194.

    Google Scholar 

  • 120 Cavallasca JA, Costa CA, Maliandi Mdel R, Contini LE, Fernandez de Carrera E, Musuruana JL. Severe infections in patients with autoimmune diseases treated with cyclophosphamide. Reumatol Clin. 2015;11:221–223.

    Google Scholar 

  • 121 Silva MF, Ferriani MP, Terreri MT, et al. A multicenter study of invasive fungal infections in patients with childhood-onset systemic lupus erythematosus. J Rheumatol. 2015;42:2296–2303.

    Google Scholar 

  • 122 Firooz N, Albert DA, Wallace DJ, Ishimori M, Berel D, Weisman MH. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus. 2011;20:588–597.

    Google Scholar 

  • 123 Serio I, Arnaud L, Mathian A, Hausfater P, Amoura Z. Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. Clin Rheumatol. 2014;33:1209–1215.

    Google Scholar 

  • 124 Beca S, Rodriguez-Pinto I, Alba MA, Cervera R, Espinosa G. Development and validation of a risk calculator to differentiate flares from infections in systemic lupus erythematosus patients with fever. Autoimmun Rev. 2015;14:586–593.

    Google Scholar 

  • 125 Murdaca G, Orsi A, Spano F, et al. Vaccine-preventable infections in systemic lupus erythematosus. Hum Vaccin Immunother. 2016;12:632–643.

    Google Scholar 

  • 126 ter Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenberg CG. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: A prospective longitudinal study. J Rheumatol. 1990;17:1642–1648.

    Google Scholar 

  • 127 Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998;41:1828–1834.

    Google Scholar 

  • 128 Mathian A, Devilliers H, Krivine A, et al. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. Arthritis Rheum. 2011;63:3502–3511.

    Google Scholar 

  • 129 Csuka D, Czirjak L, Hobor R, et al. Effective humoral immunity against diphtheria and tetanus in patients with systemic lupus erythematosus or myasthenia gravis. Mol Immunol. 2013;54:453–456.

    Google Scholar 

  • 130 Guthridge JM, Cogman A, Merrill JT, et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 2013;40:1875–1880.

    Google Scholar 

  • 131 Arnaud L, Mathian A, Devilliers H, et al. Efficacy of influenza vaccination is strongly decreased in systemic lupus erythematosus: a meta-analysis of literature data. Arthritis Rheum. 2013;65:1564.

    Google Scholar 

  • 132 Kuruma KA, Borba EF, Lopes MH, de Carvalho JF, Bonfa E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus. 2007;16:350–354.

    Google Scholar 

  • 133 Zard E, Arnaud L, Mathian A, et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. Autoimmun Rev. 2014;13:730–735.

    Google Scholar 

  • 134 Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72:659–664.

    Google Scholar 

  • 135 Soybilgic A, Onel KB, Utset T, Alexander K, Wagner-Weiner L. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J. 2013;11:29.

    Google Scholar 

  • 136 Pellegrino P, Radice S, Clementi E. Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases: A systematic review. Vaccine. 2015;33:3444–3449.

    Google Scholar 

  • 137 Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275:398–408.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Karolinska University Hospital Unit for Clinical Therapy Research, Stockholm, Sweden

    Laurent Arnaud

  2. Clinical Immunology & Rheumatology, Academic Medical Center, Amsterdam, The Netherlands

    Ronald van Vollenhoven

Authors
  1. Laurent Arnaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald van Vollenhoven
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurent Arnaud .

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Arnaud, L., van Vollenhoven, R. (2018). Specific issues. In: Advanced Handbook of Systemic Lupus Erythematosus. Adis, Cham. https://doi.org/10.1007/978-3-319-43035-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43035-5_7

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-43034-8

  • Online ISBN: 978-3-319-43035-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation